目的 探讨复方脑肽节苷脂注射液联合阿替普酶静脉溶栓治疗急性缺血性脑卒中的疗效。方法 选择2019年6月—2023年1月在河南省许昌中医院诊治的79例缺血性脑卒中患者,按照入院就诊顺序采用奇偶法把患者分为联合组40例与传统组39例。传统组给予阿替普酶静脉溶栓治疗,联合组给予复方脑肽节苷脂注射液联合阿替普酶静脉溶栓治疗,评价与记录联合组与传统组的疗效与安全性及治疗前、治疗14 d后Fugl-Meyer评定量表（FMA）与改良版Banhel评价指数（MBI）、血清β-内啡肽、前列腺素E2（PGE2）水平变化。结果 治疗14 d后联合组的总有效率更高（97.5% vs 82.1%,P<0.05）,并发症发生率更低（5.0% vs 20.5%,P<0.05）。联合组与传统组治疗14 d后的FMA与MBI评分高于治疗前（P<0.05）,联合组治疗14 d后的FMA评分、MBI评分比传统组提高（P<0.05）。联合组与传统组治疗14 d后的血清β-内啡肽、PGE2水平低于治疗前（P<0.05）,联合组治疗14 d后的血清β-内啡肽、PGE2水平低于传统组（P<0.05）。结论 复方脑肽节苷脂注射液联合阿替普酶静脉溶栓治疗急性缺血性脑卒中能提高效果,降低患者的肺部感染、尿路感染、静脉血栓、褥疮等并发症发生率,改善患者的运动与日常生活功能,还可降低患者血清β-内啡肽、PGE2水平。

Objective To explore and analysis the efficacy and safety of compound brain peptide ganglioside injection combined with alteplase intravenous thrombolysis in the treatment of acute ischemic stroke. Methods From June 2019 to January 2023,79 patients with ischemic stroke who were diagnosed and treated at Henan Xuchang Traditional Chinese Medicine Hospital were selected as the research subjects．According to the order of admission,the patients were divided into the combination group of 40 cases and the traditional group of 39 cases．The traditional group received intravenous thrombolytic therapy with alteplase,while the combination group received treatment with compound brain peptide ganglioside injection on the basis of the traditional group．The efficacy and safety and changes of the Fugl-Meyer rating Scale（FMA）and modified Banhel Evaluation Index（MBI）,serum β-endorphin,and PGE 2 levels in the combined and traditional groups were evaluated and recorded. Results After 14 days of treatment,the combined group had a higher overall response rate（97.5% vs 82.1%,P<0.05）and a lower complication rate（5.0% vs 20.5%,P<0.05）．FMA scores and MBI scores of the two groups after 14 days of treatment were higher than those before treatment（P<0.05）,and FMA scores and MBI scores of the combined group after 14 days of treatment were higher than those of the traditional group（P<0.05）．The contents of β-endorphin and prostaglandin E2 in two groups after 14 days of treatment were lower than those before treatment（P<0.05）,and the contents of β-endorphin and prostaglandin E2 in combination group after 14 days of treatment were lower than those in traditional group（P<0.05）. Conclusions The combination of compound brain peptide ganglioside injection and alteplase intravenous thrombolysis in the treatment of acute ischemic stroke can improve the treatment effect,reduce the incidence of complications such as pulmonary infections,urinary tract infections,venous thrombosis and bedsores in patients,improve patients' motor and daily life functions,and also reduce patients' serum levels of β-endorphins and prostaglandin E2．

       目的   探讨影响急性脑梗死患者接受重组组织型纤溶酶原激活剂（rt-PA）静脉溶栓治疗决策延迟的因素，并提出减少溶栓决策时间的建议。方法   采用回顾性分析方法，对泉州市第一医院2023年通过急诊收治的120例急性脑梗死患者及其家属的资料进行分析。根据溶栓决策时间，以5 min为界限，将患者分为非延迟组（62例）和延迟组（58例），并对两组资料进行比较分析。采用SPSS 23.0统计软件分析数据，运用t检验（针对连续变量）和χ ² 检验（针对分类变量）比较组间的差异。此外，通过Logistic回归分析，确定影响急性脑梗死患者静脉溶栓治疗决策的危险因素。结果   对比两组患者数据后发现，籍贯地区、冠心病史、外院转入、发病到入院时间以及决策家属数量比较差异具有统计学意义（P＜0.05）。多因素Logistic回归分析进一步揭示，非泉州籍贯地区［OR（95%CI）：9.29（2.21~38.97），P=0.002］、决策家属人数≥2人［OR（95%CI）：18.73（5.96~58.80），P＜0.001］、从外院转入［OR（95%CI）：10.26（2.09~50.42），P=0.004］以及发病到入院时间3.0~4.5 h［OR（95%CI）：4.09（1.45~11.48），P=0.008］是导致治疗决策延迟的独立危险因素。结论   患者非泉州籍贯地区、外院转入、溶栓决策家属人员≥2个、发病到入院时间3~4.5 h是溶栓决策延误的影响因素，提出优化卒中急诊抢救流程以及通过卒中宣教以缩短溶栓决策时间的建议。

       Objective  To investigate the factors influencing delays in decision-making for intravenous thrombolysis with recombinant tissue plasminogen activator（rt-PA）in patients with acute cerebral infarction and to propose  recommendations for reducing thrombolysis decision-making time．Methods  A  retrospective analysis was conducted on data from 120 patients with acute cerebral infarction admitted to the emergency department at Quanzhou First Hospital in 2023，including information from their families．Patients were divided into non-delay group （62 cases） and delay group （58 cases） based on a 5-minute threshold for thrombolysis decision-making time．Comparative analysis between the two groups was performed using SPSS 23.0 statistical software，with t-tests for continuous variables and χ ²  tests for categorical variables．Logistic  regression analysis was employed to identify  risk factors affecting decision-making for intravenous thrombolysis in these patients．Results  Statistical analysis  revealed significant differences between the two groups in terms of native region，history of coronary heart disease，transfer from other hospitals，time from onset to hospital admission，and number of family members involved in decision-making（P＜0.05）．Multivariate Logistic regression identified independent risk factors for delayed treatment decisions：non-Quanzhou native region （OR［95%CI］：9.29［2.21-38.97］，P=0.002），having two or more decision-making family members （OR［95%CI］：18.73［5.96-58.80］，P＜0.001），transfer from other hospitals （OR［95%CI］：10.26［2.09-50.42］，P=0.004），and a time from onset to hospital admission of 3-4.5 hours （OR［95%CI］：4.09［1.45-11.48］，P=0.008）．Conclusions  Factors  such as non-Quanzhou native region，transfer from other hospitals，having two or more family members involved in decision-making，and a time from onset to hospital admission of 3-4.5 hours are associated with delays in thrombolysis decision-making．Optimizing the emergency  rescue process for stroke and shortening the thrombolytic decision-making time through stroke education are suggested．